78 High Adenocarcinoma Risk After Diagnosis of Gastric MALT Lymphoma: A Long-Term Nationwide Study

Capelle, Lisette; Vries, Annemarie C. de; Looman, Caspar W.N.; Casparie, M.K.; Meijer, Gerrit A.; Kuipers, E.J.

doi:10.1016/s0016-5085(08)60067-0

Search citation statements

Order By: Relevance

Paper Sections

Select...

Gastrointestinale Lymphome1

Citation Types

Supporting

Mentioning

Contrasting

Unclassified

Year Published

2009

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Erstaunlich häufig (24 /120) traten Zweittumoren im Verlauf auf: 8 × Lymphome und 21 × solide Tumoren, davon 5 Magenkarzinome. Ein 6-fach erhöhtes Magenkarzinomrisiko bei Patienten mit einem MALT-Lymphom wurde auch in einer weiteren Studie aus den Niederlanden beobachtet [98]. Demnach sind langfristig endoskopisch-bioptische Kontrollen erforderlich, da die Nachsorge nicht nur auf ein Rezidiv des Magenlymphoms, sondern auch auf eine mögliche Karzinomentwicklung achten muss.…”

Section: Gastrointestinale Lymphomeunclassified

Gastrointestinale Onkologie – Therapieupdate 2008 / 2009

Ebert¹,

Auernhammer²,

Caca³

et al. 2009

Z Gastroenterol

View full text Add to dashboard Cite

As a consequence of recent studies the treatment of gastrointestinal cancers has become challenging and is undergoing constant changes on the basis of the results of new trials. The steering committee of the working group on gastrointestinal cancers of the Deutsche Gesellschaft für Verdauungs- und Stoffwechselkrankheiten has decided to summarise and present recent updates of the current treatment guidelines and recommendations for the most relevant gastrointestinal malignancies. In this review we have included recent findings from large trials on esophageal, gastric, pancreatic, cholangiocellular and liver cancers, as well as colorectal cancers, neuroendocrine tumours and lymphomas. This includes an update on the combination with novel targeted agents and the introduction of potential predictive biomarkers in the selection of the appropriate treatment strategy.

show abstract

Section: Gastrointestinale Lymphomeunclassified